Oral cavity quantitative histomorphometric risk classifier (ohbic) in oral cavity squamous cell carcinoma (OC-SCC)

Active Project Grant Awarded Last action

Award ID
R01CA249992
Recipient
Awarding agency
Obligated
$8,468,806

Award facts

Assistance listing
93.394 Cancer Detection and Diagnosis Research
Completion date 87% complete
Originally
Funding
  • $7,124,836.00 Federal
  • $1,343,970.00 Non-federal
Place of performance
Atlanta, GA 30322, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
In 2018, nearly 34,000 adults in the US and over 275,000 worldwide were diagnosed with oral cavity squamous cell carcinoma (OC-SCC). In the US alone >6,600 died from the disease in 2018. In addition to stage, perineural invasion, lymphovascular invasion, depth of invasion, and close or frankly positive resection margins are used to help stratify patients into low-, intermediate-, or high risk categories. Currently, all OC-SCC patients are treated primarily by surgical resection. Post-operative treatment depends on patient risk category. Low-risk patients receive surgery alone and studies have shown the benefit of port (post-operative radiation therapy) in selected patients. A retrospective analysis of 1467 patients with low-risk OC-SCC where 740 (50.4%) received port had improved overall survival compared to 727 patients treated with surgery alone. Identifying these patients and better stratifying their risk of progression is critical. Meanwhile, patients with loco-regionally advanced (i.e. intermediate and high risk) disease are treated with port as standard. Select high risk patients may be treated with concomitant chemoradiation or subsequent chemotherapy. There is thus an urgent need to develop companion diagnostic tools to better define which patients will benefit from port, or, if intermediate or high risk, who will benefit from systemic therapy intensification. Recently, our group has developed a OC-SCC histomorphometric based image risk classifier (ohbic) that uses computerized measurements of nuclear orientation, texture, shape, architecture from digital images of h & e-stained tumor sections to identify patients who are likely to recur versus those who are not. Ohbic was trained and validated on n=115 OC-SCC patients, and IT had a 2 and 7-fold higher-correlation with disease specific survival compared to the 7TH edition ajcc n- and t-stage (clinical variables used in patient prognosis). In this NIH R01, we seek to further improve the prognostic and predictive accuracy of ohbic by incorporating new classes of image features relating to stromal morphology, pattern of invasion at the tumor leading edge, density and patterns of tumor infiltrating lymphocytes, and tumor cell multi-nucleation, features now recognized as potential histopathological markers of prognostic relevance in OC-SCC. Additionally, we seek to 1) validate ohbic as prognostic of survival in clinically defined low-risk patients and identify those low-risk patients who would benefit from port and 2) validate ohbic as not only prognostic of survival but also predictive of benefit from chemotherapeutic intensification for patients with loco-regionally advanced disease. This partnership will leverage long-standing collaborations in (1) digital pathomics from the madabhushi group at case western reserve, (2) surgical pathology and oncology expertise in oral cancer from vanderbilt university, cleveland clinic, SAN francisco VA, and tata memorial centre, mumbai to establish ohbic as a tissue non-destructive and affordable precision medicine (APM) solution for OC-SCC patients.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $600,267 $0
Amendment $580,084 $0
Amendment $0 $0
Amendment $0 $0
Amendment $599,835 $0
Amendment -$599,835 $0
Amendment $599,835 $0
Amendment -$599,835 $0
Amendment $654,803 $0
Amendment $654,803 $0
Amendment $654,803 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $0 $0
Amendment $52,740 $0
Amendment $52,740 $52,740
Amendment $52,740 $0
Amendment $52,740 $0
Amendment $593,328 $0
Amendment $593,328 $593,328
Amendment $593,328 $0
Amendment $593,328 $0
Amendment $697,902 $0
Original award $697,902 $697,902
Show all 27

Subawards

Subrecipient Amount Awarded
Georgia TECH Research Corp Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity $16,653
Georgia TECH Research Corp $38,726
Georgia TECH Research Corp $38,726
Case Western Reserve University $22,624
Mayo Clinic $37,459
Georgia TECH Research Corp $53,621
Mayo Clinic $18,730
Tata Memorial Centre $34,570
The Regents Of The University Of California. San Francisco $29,076
Northern California Institute For Research And Education, Inc. $23,432
The Ohio State University $19,757
Georgia TECH Research Corp $23,390
Case Western Reserve University $11,779
Tata Memorial Centre $95,386
Vanderbilt University Medical Center $56,331
Northern California Institute For Research And Education, Inc. $35,990
The Regents Of The University Of California. San Francisco $33,631
Case Western Reserve University $26,972
Vanderbilt University Medical Center $52,603
The Regents Of The University Of California. San Francisco $29,075
Northern California Institute For Research And Education, Inc. $22,857
Show all 21

Quick answers

Who received award R01CA249992?

R01CA249992 was awarded to Emory University by National Cancer Institute (National Institutes of Health) on December 30, 2020.

How much is award R01CA249992 worth?

$8,468,806 has been obligated on R01CA249992: $7,124,836 in federal funding and $1,343,970 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login